Owned by the Association for International Promotion & Study in Tumors (APSIT)
Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is bel...
Citation: Journal of Experimental & Clinical Cancer Research 2021 40:138